MX2022001133A - Regimen de dosificacion para un inhibidor de indolamina 2,3-dioxigenasa (ido). - Google Patents
Regimen de dosificacion para un inhibidor de indolamina 2,3-dioxigenasa (ido).Info
- Publication number
- MX2022001133A MX2022001133A MX2022001133A MX2022001133A MX2022001133A MX 2022001133 A MX2022001133 A MX 2022001133A MX 2022001133 A MX2022001133 A MX 2022001133A MX 2022001133 A MX2022001133 A MX 2022001133A MX 2022001133 A MX2022001133 A MX 2022001133A
- Authority
- MX
- Mexico
- Prior art keywords
- dosing regimen
- ido inhibitor
- antibody
- epacadostat
- binds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Abstract
La presente descripción se relaciona con regímenes de dosificación para el tratamiento del cáncer mediante la administración de epacadostat en combinación con un anticuerpo, o un fragmento de anticuerpo del mismo, que se une a la PD-1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962881518P | 2019-08-01 | 2019-08-01 | |
PCT/US2020/044533 WO2021022172A1 (en) | 2019-08-01 | 2020-07-31 | A dosing regimen for an ido inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022001133A true MX2022001133A (es) | 2022-04-25 |
Family
ID=72139706
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022001133A MX2022001133A (es) | 2019-08-01 | 2020-07-31 | Regimen de dosificacion para un inhibidor de indolamina 2,3-dioxigenasa (ido). |
Country Status (10)
Country | Link |
---|---|
US (1) | US20210030869A1 (es) |
EP (1) | EP4007602A1 (es) |
JP (1) | JP2022543062A (es) |
KR (1) | KR20220044527A (es) |
CN (1) | CN114502196A (es) |
AU (1) | AU2020319875A1 (es) |
CA (1) | CA3148776A1 (es) |
IL (1) | IL290006A (es) |
MX (1) | MX2022001133A (es) |
WO (1) | WO2021022172A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI1879573T1 (sl) | 2005-05-10 | 2013-04-30 | Incyte Corporation Experimental Station | Modulatorji indolamin 2,3-dioksigenaze in postopki za uporabo le-te |
ES2524266T3 (es) | 2008-07-08 | 2014-12-04 | Incyte Corporation | 1,2,5-Oxadiazoles como inhibidores de la indoleamina 2,3-dioxigenasa |
US20220010028A1 (en) * | 2020-07-09 | 2022-01-13 | The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Compositions and methods for treating fibroids |
US20230025464A1 (en) * | 2021-07-09 | 2023-01-26 | Macrogenics, Inc. | Pharmaceutical compositions of a pd-1 antibody and use of the same |
KR20240042109A (ko) * | 2021-08-13 | 2024-04-01 | 어젠시스 인코포레이티드 | 191P4D12 단백질에 결합하는 항체 약물 접합체[Antibody Drug Conjugate, ADC]로 비근침윤성 방광암[Non-muscle invasive bladder cancer, NMIBC]을 치료하는 방법 |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5156840A (en) | 1982-03-09 | 1992-10-20 | Cytogen Corporation | Amine-containing porphyrin derivatives |
US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
EP0617706B1 (en) | 1991-11-25 | 2001-10-17 | Enzon, Inc. | Multivalent antigen-binding proteins |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
ES2176484T3 (es) | 1995-08-18 | 2002-12-01 | Morphosys Ag | Bancos de proteinas/(poli)peptidos. |
DE69942097D1 (de) | 1998-08-11 | 2010-04-15 | Novartis Ag | Isochinoline derivate mit angiogenesis-hemmender wirkung |
US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
DE60230890D1 (de) | 2001-09-19 | 2009-03-05 | Aventis Pharma Sa | Indolizine als kinaseproteinhemmer |
ATE335490T1 (de) | 2001-10-30 | 2006-09-15 | Novartis Pharma Gmbh | Staurosporin-derivate als hemmer der flt3- rezeptor-tyrosinkinase-wirkung |
IL162721A0 (en) | 2002-01-22 | 2005-11-20 | Warner Lambert Co | 2-(Pyridin-2-ylamino)-pyridoÄ2,3-dÜpyrimidin-7-ones |
PE20040522A1 (es) | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
TWI335913B (en) | 2002-11-15 | 2011-01-11 | Vertex Pharma | Diaminotriazoles useful as inhibitors of protein kinases |
UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
EP1585767A2 (en) | 2003-01-16 | 2005-10-19 | Genentech, Inc. | Synthetic antibody phage libraries |
WO2004072266A2 (en) | 2003-02-13 | 2004-08-26 | Kalobios Inc. | Antibody affinity engineering by serial epitope-guided complementarity replacement |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
EP2239271A1 (en) | 2003-06-13 | 2010-10-13 | Biogen Idec MA Inc. | Aglycosyl anti-CD154 (CD40 ligand) antibodies and uses thereof |
CA2536408A1 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
AR045944A1 (es) | 2003-09-24 | 2005-11-16 | Novartis Ag | Derivados de isoquinolina 1.4-disustituidas |
JP2008520612A (ja) | 2004-11-24 | 2008-06-19 | ノバルティス アクチエンゲゼルシャフト | JAK阻害剤およびBcr−Abl、Flt−3、FAKまたはRAFキナーゼ阻害剤のうち少なくとも1個の組合せ |
KR20100095020A (ko) | 2007-12-19 | 2010-08-27 | 암젠 인크 | 세포 주기 억제제로서의 융합된 피리딘, 피리미딘 및 트리아진 화합물 |
ES2524266T3 (es) | 2008-07-08 | 2014-12-04 | Incyte Corporation | 1,2,5-Oxadiazoles como inhibidores de la indoleamina 2,3-dioxigenasa |
PA8852901A1 (es) | 2008-12-22 | 2010-07-27 | Lilly Co Eli | Inhibidores de proteina cinasa |
UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
CA2815084C (en) | 2010-10-25 | 2017-05-09 | G1 Therapeutics, Inc. | Cdk inhibitors |
DK2937349T3 (en) | 2011-03-23 | 2017-02-20 | Amgen Inc | CONDENSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3 |
SG10201803874PA (en) | 2013-11-08 | 2018-07-30 | Incyte Holdings Corp | Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor |
HRP20211645T1 (hr) | 2015-07-30 | 2022-02-04 | Macrogenics, Inc. | Molekule za vezanje pd-1 i postupci za njihovu uporabu |
MA43172A (fr) * | 2015-11-04 | 2018-09-12 | Incyte Corp | Compositions pharmaceutiques et méthodes d'inhibition d'indolamine 2,3-dioxygénase et leurs indications |
WO2017214092A1 (en) * | 2016-06-07 | 2017-12-14 | Macrogenics, Inc. | Combination therapy |
AU2019205904A1 (en) * | 2018-01-05 | 2020-06-18 | Dicerna Pharmaceuticals, Inc. | Reducing beta-catenin and IDO expression to potentiate immunotherapy |
-
2020
- 2020-07-31 KR KR1020227006814A patent/KR20220044527A/ko active Search and Examination
- 2020-07-31 WO PCT/US2020/044533 patent/WO2021022172A1/en unknown
- 2020-07-31 CN CN202080065914.XA patent/CN114502196A/zh active Pending
- 2020-07-31 AU AU2020319875A patent/AU2020319875A1/en active Pending
- 2020-07-31 US US16/944,953 patent/US20210030869A1/en not_active Abandoned
- 2020-07-31 CA CA3148776A patent/CA3148776A1/en active Pending
- 2020-07-31 MX MX2022001133A patent/MX2022001133A/es unknown
- 2020-07-31 EP EP20757758.6A patent/EP4007602A1/en active Pending
- 2020-07-31 JP JP2022506474A patent/JP2022543062A/ja active Pending
-
2022
- 2022-01-20 IL IL290006A patent/IL290006A/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20210030869A1 (en) | 2021-02-04 |
JP2022543062A (ja) | 2022-10-07 |
IL290006A (en) | 2022-03-01 |
WO2021022172A1 (en) | 2021-02-04 |
KR20220044527A (ko) | 2022-04-08 |
CA3148776A1 (en) | 2021-02-04 |
EP4007602A1 (en) | 2022-06-08 |
CN114502196A (zh) | 2022-05-13 |
AU2020319875A1 (en) | 2022-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022001133A (es) | Regimen de dosificacion para un inhibidor de indolamina 2,3-dioxigenasa (ido). | |
AU2022200570B2 (en) | Compositions and methods for treating anemia | |
PH12020500075A1 (en) | Checkpoint inhibitor bispecific antibodies | |
MX2020010444A (es) | Complejos de péptidos bicíclicos en heterotándem. | |
MX2017015811A (es) | Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4). | |
PE20181326A1 (es) | Anticuerpos que se unen especificamente a pd-1 y sus usos | |
MX2020006668A (es) | Anticuerpos para lilrb2. | |
MX2019008701A (es) | Terapia de combinacion que involucra compuestos macrociclicos de diarilo. | |
NZ738979A (en) | Pd-1 antibodies | |
CO2019002369A2 (es) | Anticuerpo que se une específicamente a pd-1 y fragmento funcional del mismo | |
MY192705A (en) | Compositions and methods for treating anemia | |
MX2018003713A (es) | Prevencion, tratamiento y reduccion del dolor de cabeza postraumatico (persistente). | |
MX2019003338A (es) | Tratamiento de cefalea en racimos. | |
PH12020551661A1 (en) | Anti-pd-l1 antibody and use thereof | |
EA201990374A1 (ru) | Комбинация антитела против cd20, ингибитора pi3-киназы-дельта и антитела против pd-1 или против pd-l1 для лечения гематологических раков | |
MX2018014863A (es) | Régimen de dosificación para proteína de fusión de tcr especifico de gp100 - scfv anti - cd3. | |
MX2018008008A (es) | Combinacion del inhibidor hdac y anticuerpo-pd-l1 para el tratamiento de cancer ovarico. | |
MX2021005236A (es) | Regimen de dosificacion de anticuerpo anti-tigit para el tratamiento de cancer. | |
ZA202206993B (en) | Anti-lilrb1 antibody and uses thereof | |
BR112017011538A2 (pt) | combinação de anticorpos anti-cs1 e anti-pd1 para tratar câncer (mieloma) | |
MX2021016098A (es) | Moleculas de anticuerpos humanizados contra cd138 y usos de las mismas. | |
MX2021003298A (es) | Métodos para revertir la actividad ticagrelor. | |
MX2021000797A (es) | Anticuerpos agonistas de cd226. | |
EA201891529A1 (ru) | Композиции и способы обнаружения и лечения рака яичников | |
MX2020009864A (es) | Anticuerpos anti-cd137 para combinacion con anticuerpos anti-pd-1. |